Dermira to Present Data from DRM01 and DRM04 Clinical Programs at Fall Clinical Dermatology Conference
October 13, 2016 07:30 ET
|
Dermira, Inc.
MENLO PARK, Calif., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
October 03, 2016 02:00 ET
|
Dermira, Inc.
BRUSSELS, Belgium and MENLO PARK, Calif., Oct. 03, 2016 (GLOBE NEWSWIRE) -- UCB (Euronext:UCB) and Dermira, Inc. (NASDAQ:DERM) today announced topline results from CIMPASI-2, a Phase 3,...
Dermira Presents Data from DRM04 Phase 3 Clinical Program in Late-Breaking News Session at European Academy of Dermatology and Venereology Congress
October 01, 2016 03:05 ET
|
Dermira, Inc.
MENLO PARK, Calif., Oct. 01, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira to Present Data from DRM04 Phase 3 Clinical Trials at Late-Breaking News Session at European Academy of Dermatology and Venereology Congress
September 28, 2016 07:30 ET
|
Dermira, Inc.
MENLO PARK, Calif., Sept. 28, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira Licenses DRM04 to Maruho for Hyperhidrosis in Japan
September 20, 2016 16:05 ET
|
Dermira, Inc.
Terms include $25 million upfront license payment to DermiraMaruho to fund all development and commercial costs for DRM04 in Japan MENLO PARK, Calif., Sept. 20, 2016 (GLOBE NEWSWIRE) --...
Dermira Acquires Option to License Exclusive Rights for up to Three Early-Stage Programs from Takeda
September 12, 2016 07:30 ET
|
Dermira, Inc.
MENLO PARK, Calif., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira Reports Second Quarter 2016 Financial Results and Provides Corporate Update
August 08, 2016 16:12 ET
|
Dermira, Inc.
Reported Topline Results for Two Late-Stage Clinical ProgramsRaised Approximately $136 Million in Net Proceeds from Follow-on Public OfferingUpdates Guidance for Topline Phase 3 CIMZIA®...
Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 13, 2016 16:05 ET
|
Dermira, Inc.
MENLO PARK, Calif., June 13, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira Prices $126 Million Public Offering of Common Stock
June 08, 2016 07:00 ET
|
Dermira, Inc.
MENLO PARK, Calif., June 08, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira to Present Preclinical Data from DRM01 Acne Program at the Society for Investigative Dermatology 75th Annual Meeting
May 11, 2016 16:05 ET
|
Dermira, Inc.
MENLO PARK, Calif., May 11, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...